Details

Autor(en) / Beteiligte

• Tsai, Tzu-Hsien
• Lu, Cheng-Hsien
• Wallace, Christopher Glenn
• Chang, Wen-Neng
• Chen, Shu-Feng
• Huang, Chi-Ren
• Tsai, Nai-Wen
• Lan, Min-Yu
• Sung, Pei-Hsun
• Liu, Chu-Feng
• Yip, Hon-Kan

Titel

Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial

Ist Teil von

• Critical care (London, England), 2015-02, Vol.19 (1), p.49-49, Article 49

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2015

Quelle

SpringerLink

Beschreibungen/Notizen

• Mortality and disability following ischemic stroke (IS) remains unacceptably high with respect to the conventional therapies. This study tested the effect of erythropoietin (EPO) on long-term neurological outcome in patients after acute IS. This study aimed to evaluate the safety and efficacy of two consecutive doses of EPO (5,000 IU/dose, subcutaneously administered at 48 hours and 72 hours after acute IS) on improving the 90-day combined endpoint of recurrent stroke or death that has been previously reported. A secondary objective was to evaluate the long-term (that is, five years) outcome of patients who received EPO. This was a prospective, randomized, placebo-controlled trial that was conducted between October 2008 and March 2010 in a tertiary referral center. IS stroke patients who were eligible for EPO therapy were enrolled into the study. The results showed that long-term recurrent stroke and mortality did not differ between group 1 (placebo-control; n = 71) and group 2 (EPO-treated; n = 71). Long-term Barthel index of <35 (defining a severe neurological deficit) was lower in group 2 than group 1 (P = 0.007). Multiple-stepwise logistic-regression analysis showed that EPO therapy was significantly and independently predictive of freedom from a Barthel index of <35 (P = 0.029). Long-term major adverse neurological event (MANE; defined as: death, recurrent stroke, or long-term Barthel index < 35) was lower in group 2 than group 1 (P = 0.04). Log-Rank test showed that MANE-free rate was higher in group 2 than group 1 (P = 0.031). Multiple-stepwise Cox-regression analysis showed that EPO therapy and higher Barthel Index at day 90 were independently predictive of freedom from long-term MANE (all P <0.04). EPO therapy significantly improved long-term neurological outcomes in patients after IS. ISRCTN71371114 . Registered 10 October 2008.